hta
EMA looks to sharpen HTA data output
November 20, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, EMA, NICE, hta, transparency
The European Medicines Agency (EMA) has deepened its partnership with the European network for Health Technology Assessment (EUnetHTA) as it …
EU orphan designations rise
February 19, 2013Research and Development, Sales and Marketing COMP, EMA, Orphan, hta
The number of orphan drug designations in the EU is set to rise to record levels this year, according to …
ABPI slams NICE International
August 20, 2012Sales and Marketing ABPI, NICE, NICE International, Romania, hta
The ABPI has expressed concerns over the remit of NICE International and its affect on global markets. NICE International is …
NICE no for Avastin in breast cancer
December 8, 2010Sales and Marketing NICE, Roche, avastin, bevacizumab, breast cancer, health technology assessment, hta
NICE has refused to back Roche’s Avastin for use in breast cancer patients citing the blockbuster drug’s high cost and …
Change is needed, concedes NICE chief, but defends record
November 30, 2010Sales and Marketing Andrew Dillon, NHS reform, NICE, cost-effectiveness, health technology assessment, hta, value-based pricing
The chief executive of NICE acknowledges changes are needed in how drugs are assessed in the UK – including more …
Irish cost-effectiveness guidelines published
November 15, 2010Sales and Marketing Dr Mairin Ryan, Economic Evaluation of Health Technologies, HIQA, Health Information and Quality Authority, IPHA, Ireland, Irish Pharmaceutical Healthcare Association, NICE, hta
The Irish government has published new health technology assessment guidelines to help decision-makers estimate the cost-effectiveness of medical treatments. The …
NICE limits access to cancer drugs, study confirms
November 10, 2010Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, IPSOR, Maximilian Lebmeier, NICE, hta
NICE became more restrictive in its assessment of new cancer drugs between 2007 and 2009, a new report suggests. The …
Pharma engages HTA bodies in early-stage drug discussions
October 27, 2010Research and Development, Sales and Marketing Andrew Witty, AstraZeneca, EMA, European Medicines Agency, GlaxoSmithKline, Johnson & Johnson, health technology assessment, hta
Three pharma companies are taking part in a new pilot to harmonise European standards in health technology assessment (HTA). AstraZeneca, …
European call for greater HTA co-operation
July 9, 2010Sales and Marketing hta
The European Commissioner who oversees the pharma sector has called for greater co-operation on health technology assessment. John Dalli, the …
Europe must move on from ‘simplistic’ pricing
June 22, 2010Research and Development Europe, hta, pricing, pricing & Reimbursement
GSK chief executive Andrew Witty has called on European governments to scrap outdated pricing systems and embrace newer methods, in …
Implementing value-based pricing in the UK
June 14, 2010Sales and Marketing hta, pricing, value
The UK has a strong history of innovation in medicines and it is vital to the economy that this continues …
NICE warns industry on cost-effectiveness
February 9, 2010Sales and Marketing BMS, Janssen, NICE, Novartis, hta
NICE has turned down three drugs on cost grounds and has urged the pharma industry to do more to help …
Promising new drugs could bypass UK approval process
December 23, 2009Sales and Marketing MHRA, MISG, hta, market access
UK patients could next year be given access to drugs that are still in the later stages of clinical development, …
EU should require all trials to be registered, says IQWiG
December 1, 2009Sales and Marketing Germany, IQWIG, health economics, hta
Germany’s Institute for Quality and Efficiency in Health Care (IQWiG) has said that registration and publication of all clinical trials …
Kennedy calls for overhaul of NICE processes
July 23, 2009Research and Development, Sales and Marketing NICE, hta
NICE has come under fire over its lack of transparency and its relationship with the industry, following an inquiry by …
